Terms: = Colorectal cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Clinical Outcome
72 results:
1. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.
Li Y; Shen Z; Chai Z; Zhan Y; Zhang Y; Liu Z; Liu Y; Li Z; Lin M; Zhang Z; Liu W; Guan S; Zhang J; Qian J; Ding Y; Li G; Fang Y; Deng H
Gut; 2023 Nov; 72(12):2307-2320. PubMed ID: 37507218
[TBL] [Abstract] [Full Text] [Related]
2. Depletion of Fibroblast Growth Factor 12 Restrains the Viability, Stemness, and Motility of colorectal cancer.
Gao X; Liao Z; Su R; Zheng D; Huang G; Huang Z; Cheng X
Biomed Res Int; 2022; 2022():9948461. PubMed ID: 35860801
[TBL] [Abstract] [Full Text] [Related]
3. Integrated Analysis of DNA Repair Genes Identifies SLC6A1 as a New Marker for the clinical outcome of Patients with colorectal cancer.
Wang QQ; Wei Y; Luo LP; Li X; Jiang WJ
Dis Markers; 2022; 2022():4952812. PubMed ID: 35251372
[TBL] [Abstract] [Full Text] [Related]
4. Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer.
Ogawa M; Tanaka A; Namba K; Shia J; Wang JY; Roehrl MHA
Sci Rep; 2022 Feb; 12(1):2767. PubMed ID: 35177765
[TBL] [Abstract] [Full Text] [Related]
5. Identification and functional analysis of lncRNAs and mRNAs between tumorigenesis and metastasis in CRC.
Liu H; Tian Y; Li J; Zhang G; Liu Q; Yang M; Yue L; Cao Q; Zhang G; Cheng Y; Kong N; Fang L; Li S; Sun Q
Aging (Albany NY); 2021 Dec; 13(24):25859-25885. PubMed ID: 34954693
[TBL] [Abstract] [Full Text] [Related]
6. A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic colorectal cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results.
Wein A; Stoehr R; Kersting S; Siebler J; Merkel S; Busse D; Wolff K; Ostermeier N; Neufert C; Vitali F; Eckstein M; Roth JP; Anhut P; Schreiner W; Uder M; Hartmann A; Neurath MF; Grützmann R
Oncology; 2022; 100(1):1-11. PubMed ID: 34670215
[TBL] [Abstract] [Full Text] [Related]
7. Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve clinical cancer Care.
Chakraborty S; Ecker BL; Seier K; Aveson VG; Balachandran VP; Drebin JA; D'Angelica MI; Kingham TP; Sigel CS; Soares KC; Vakiani E; Wei AC; Chandwani R; Gonen M; Shen R; Jarnagin WR
Clin Cancer Res; 2021 Nov; 27(21):5891-5899. PubMed ID: 34433650
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study.
García-Alfonso P; García-González G; Gallego I; Peligros MI; Ortega L; Torres Pérez-Solero G; Sandoval C; Muñoz Martin A; Blanco Codesido M; Calvo Ferrándiz A; Martin M
Clin Transl Oncol; 2021 Jan; 23(1):122-129. PubMed ID: 32519179
[TBL] [Abstract] [Full Text] [Related]
9. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon cancer.
Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
[TBL] [Abstract] [Full Text] [Related]
10. GATA1 promotes colorectal cancer cell proliferation, migration and invasion via activating AKT signaling pathway.
Yu J; Liu M; Liu H; Zhou L
Mol Cell Biochem; 2019 Jul; 457(1-2):191-199. PubMed ID: 31069596
[TBL] [Abstract] [Full Text] [Related]
11. RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.
Mini E; Lapucci A; Perrone G; D'Aurizio R; Napoli C; Brugia M; Landini I; Tassi R; Picariello L; Simi L; Mancini I; Messerini L; Magi A; Pinzani P; Mazzei T; Tonelli F; Nobili S
Int J Cancer; 2019 Nov; 145(9):2580-2593. PubMed ID: 30973654
[TBL] [Abstract] [Full Text] [Related]
12. A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient.
Hayashi N; Kuroda Y; Saito T; Tsuruda Y; Niida A; Otsu H; Eguchi H; Masuda T; Suzuki Y; Natsugoe S; Mimori K
Surg Today; 2019 Sep; 49(9):738-747. PubMed ID: 30843125
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Kosumi K; Hamada T; Zhang S; Liu L; da Silva A; Koh H; Twombly TS; Mima K; Morikawa T; Song M; Nowak JA; Nishihara R; Saltz LB; Niedzwiecki D; Ou FS; Zemla T; Mayer RJ; Baba H; Ng K; Giannakis M; Zhang X; Wu K; Giovannucci EL; Chan AT; Fuchs CS; Meyerhardt JA; Ogino S
Eur J Cancer; 2019 Apr; 111():82-93. PubMed ID: 30826660
[TBL] [Abstract] [Full Text] [Related]
14. The Amount of Bifidobacterium Genus in colorectal Carcinoma Tissue in Relation to Tumor Characteristics and clinical outcome.
Kosumi K; Hamada T; Koh H; Borowsky J; Bullman S; Twombly TS; Nevo D; Masugi Y; Liu L; da Silva A; Chen Y; Du C; Gu M; Li C; Li W; Liu H; Shi Y; Mima K; Song M; Nosho K; Nowak JA; Nishihara R; Baba H; Zhang X; Wu K; Wang M; Huttenhower C; Garrett WS; Meyerson ML; Lennerz JK; Giannakis M; Chan AT; Meyerhardt JA; Fuchs CS; Ogino S
Am J Pathol; 2018 Dec; 188(12):2839-2852. PubMed ID: 30243655
[TBL] [Abstract] [Full Text] [Related]
15. Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour.
Hamada T; Liu L; Nowak JA; Mima K; Cao Y; Ng K; Twombly TS; Song M; Jung S; Dou R; Masugi Y; Kosumi K; Shi Y; da Silva A; Gu M; Li W; Keum N; Wu K; Nosho K; Inamura K; Meyerhardt JA; Nevo D; Wang M; Giannakis M; Chan AT; Giovannucci EL; Fuchs CS; Nishihara R; Zhang X; Ogino S
Eur J Cancer; 2018 Nov; 103():98-107. PubMed ID: 30219720
[TBL] [Abstract] [Full Text] [Related]
16. clinical Impact and Prognostic Role of KRAS/BRAF/pik3ca Mutations in Stage I colorectal cancer.
Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
[TBL] [Abstract] [Full Text] [Related]
17.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract] [Full Text] [Related]
18. clinical Impact of pi3k/BRAF Mutations in RAS Wild Metastatic colorectal cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract] [Full Text] [Related]
19. Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer.
Kim D; Kim SY; Lee JS; Hong YS; Kim JE; Kim KP; Kim J; Jang SJ; Yoon YK; Kim TW
BMC Gastroenterol; 2017 Nov; 17(1):121. PubMed ID: 29169325
[TBL] [Abstract] [Full Text] [Related]
20. Tumor Heterogeneity Predicts Metastatic Potential in colorectal cancer.
Joung JG; Oh BY; Hong HK; Al-Khalidi H; Al-Alem F; Lee HO; Bae JS; Kim J; Cha HU; Alotaibi M; Cho YB; Hassanain M; Park WY; Lee WY
Clin Cancer Res; 2017 Dec; 23(23):7209-7216. PubMed ID: 28939741
[No Abstract] [Full Text] [Related]
[Next]
